Clinical Trial Update: Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating PEG-IFN-SA plus ribavirin for chronic hepatitis C has completed; no efficacy or safety results are described in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG-IFN-SA (pegylated interferon-alpha)
• Ribavirin (ribavirin)

Snippet

Sponsor: Beijing Kawin Technology Share-Holding Co., Ltd. | Conditions: Chronic Hepatitis c | Phase 3 | Status: COMPLETED